EUVIMEDEUVIMED entdecken
Crossref

Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development

Stephen M Hahn, Norman E Sharpless iD, Christer Svedman, William B Capra, Mark Lee iD, Mark A Socinski iD

Journal of Clinical Oncology · 05.08.2026

DOI: 10.1200/jco-26-01081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 05.08.2026. Verfasst von Stephen M Hahn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nucleus RadioPharma, Davidson, NC. Die Arbeit nennt 39 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Nucleus RadioPharma, Davidson, NC.
  • Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC.
  • N-Power Medicine Inc, Redwood City, CA.
  • AdventHealth Cancer Institute, Orlando, FL.

ORCID-Profile: Norman E Sharpless, Mark Lee, Mark A Socinski

Zitieren

APA

Hahn, S. M., Sharpless, N. E., Svedman, C., Capra, W. B., Lee, M., & Socinski, M. A. (2026). Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01081

Vancouver

Hahn SM, Sharpless NE, Svedman C, Capra WB, Lee M, Socinski MA. Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01081

BibTeX
@article{Hahn2026,
  author = {Hahn, Stephen M and Sharpless, Norman E and Svedman, Christer and Capra, William B and Lee, Mark and Socinski, Mark A},
  title = {Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-01081}
}
Kostenlos starten →